Adjunct membership is for researchers employed by other institutions who collaborate with IDM Members to the extent that some of their own staff and/or postgraduate students may work within the IDM; for 3-year terms, which are renewable.
ANDRADE, Prof Bruno de Bezerril
Professor of Pathology, School of Medicine, Faculdade de Tecnologia e Ciências, Salvador, Brazil.
He is a clinical human immunologist specializing in biomarker discovery. His research is focused on the inflammatory responses in human chronic infections. Specifically, he is dedicated to identifying reliable host biomarkers that can predict susceptibility to infection and disease severity in tuberculosis (TB) and HIV. In addition, his research goals include identification of host molecules tightly linked to the pathogenesis of TB and HIV which can be targeted in host-directed therapies to reduce immunopathology. His research approaches combine epidemiological studies with cellular and humoral immunological assays.
BARRY III, Dr Clifton
PhD, Section Chief and Senior Investigator, Tuberculosis Research Section (TRS), National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health (NIH).
Areas of interest span the basic sciences of chemistry, biochemistry and microbiology, through to pharmacology and clinical medicine, in the areas of mycobacterial pathogenesis and TB drug discovery research.
BROWN, Prof Gordon
PhD, FRS, FMedSci, FRSB, FAAM, FRSE, RSSAf, Director MRC Centre for Medical Mycology at the University of Exeter and Director of the AFGrica Unit at The University of Cape Town (UCT). Honorary Professor at UCT.
His primary research interests are C-type lectin receptors and their role in homeostasis and immunity, with a particular focus on antifungal immunity.
GRAY, Prof Glenda
MBBCH, FCP (Paeds) SA. Executive Director Perinatal HIV Research Unit, Wits Health Consortium, University of Witwatersrand; Associate Professor, Department of Paediatrics, University of Witwatersrand, South Africa; HVTN Director of International Programmes; HVTN Co-Principal Investigator; Chair of the standing committee on Health, ASSAF.
Her Research Unit is involved with clinical research, epidemiology and operational research, and is a treatment site for HIV infected adults and children. Her research interests include HIV vaccine research, microbicide research and other biomedical and behavioural interventions, and she is an investigator in testing two HIV vaccine regimens in late stage clinical development. Her TB research includes examining new agents to prevent TB, TB prophylaxis and TB vaccine evaluation.
GROBUSCH, Prof Martin
Professor, Dr. Med. (M.D.), PhD, M.Sc. (Lond), DTM&H (Lond), FRCP (Lond). Specialist in Internal Medicine, Infectious Diseases, Tropical Medicine. Full Professor and Chair of Tropical Medicine and Travel Medicine and Head, Center of Tropical Medicine and Travel Medicine, Amsterdam Medical Centre, University of Amsterdam in the Netherlands.
He has been an author on over 150 manuscripts in the field of infectious diseases and has an extensive track record in infectious diseases research and practice covering clinical, laboratory and epidemiological aspects.
LESLIE, Dr Al
Principal investigator Africa Health Research Institute (AHRI), Durban, South Africa; Associate Professor, University of KwaZulu Natal, Durban, South Africa; Wellcome Trust senior Fellow, department of infection and immunity, University College London, UK.
He is an HIV and TB immunologist focused on studying the immune response to these pathogens in affected tissues, and how this relates to what can be observed from the blood. The research goal is to improve understanding of the immunopathology of TB and HIV, using this information to aid in developing novel therapeutic approaches and diagnostic biomarkers.
MOORE, A/Prof Penny
South African Research Chair in Viral Host Dynamics, Faculty of Health Sciences, University of Witwatersrand and National Institute for Communicable Diseases
Her current research focuses on HIV broadly neutralising antibodies and their interplay with the evolving virus. Recent studies published in PloS Pathogens, Nature and Nature Medicine have highlighted the role of viral escape in creating new epitopes and immunotypes, thereby driving the development of neutralisation breadth, with implications for HIV vaccine design.
NICOL, Prof Mark
School of Biomedical Sciences, Division of Infection and Immunity, University of Western Australia; Professor in Microbiology.
Research interest in tuberculosis and in developing and testing point of care diagnostics suitable for the developing world.
REDD, Dr Andrew
PhD, Staff Scientist in International HIV and STD Section, National Institute of Allergy and Infectious Diseases at the US National Institutes of Health; Assistant Professor of Medicine at Johns Hopkins University.
His research is focused on better understanding HIV transmission and disease dynamics with a special concentration on HIV superinfection, latent HIV infection, and the role of the virus in HIV+ organ transplantation.
TROMP, Prof Gerardus
PhD (Rutgers), FAHA. Professor in Bioinformatics at the South African Tuberculosis Bioinformatics Initiative (SATBBI), Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University.
Extensive experience in bioinformatics, gene expression data and epigenetic analyses. His mandate through his appointment is to provide lead bioinformatics support on various programmes and initiative, developing a sustainable group of bioinformaticians supporting TB and related research.
WILKINSON, A/Prof Katalin
Principal Research Scientist at The Francis Crick Institute London; Honorary Associate Professor, Division of Infection and Immunity, University College London; Honorary Associate Professor, Department of Medicine, University of Cape Town.
Her research focuses on the immunology of HIV-associated tuberculosis (TB). More specifically, the reconstitution of the immune response during antiretroviral treatment, in order to identify correlates of protection (including immune mechanisms that lead to reduced susceptibility to TB), and pathogenesis (such as the Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome, TB-IRIS); the biosignature of the TB infection spectrum, from latent infection to active disease; preventing TB infection in HIV infected people more effectively; and the pathogenesis of tuberculous meningitis and pericarditis.